Results 231 to 240 of about 177,264 (261)

The safety of phosphodiesterase type 5 inhibitors for erectile dysfunction

Expert Opinion on Drug Safety, 2016
E. Ventimiglia, P. Capogrosso, F. Montorsi, A. Salonia   +3 more
semanticscholar   +1 more source

Type IV pilus structure and bacterial pathogenicity

Nature Reviews Microbiology, 2004
Lisa Craig, John A Tainer
exaly  

Phosphodiesterase type-5 inhibitors

2016
openaire   +1 more source

Type 2 diabetes as an inflammatory disease

Nature Reviews Immunology, 2011
Marc Y Donath, Steven E Shoelson
exaly  

Phosphodiesterase Type 5 Inhibitors and the Risk of Melanoma Skin Cancer.

European Urology, 2016
Yi Lian, H. Yin, M. Pollak, S. Carrier, R. Platt, S. Suissa, L. Azoulay   +6 more
semanticscholar   +1 more source

Type VI secretion system effectors: poisons with a purpose

Nature Reviews Microbiology, 2014
Alistair B Russell, S Brook Peterson, Joseph D Mougous   +2 more
exaly  

The selection and function of cell type-specific enhancers

Nature Reviews Molecular Cell Biology, 2015
Sven Heinz, Casey E Romanoski, Christopher Benner   +2 more
exaly  

Risk of sudden sensorineural hearing loss in adults using phosphodiesterase type 5 inhibitors: Population‐based cohort study

Pharmacoepidemiology and Drug Safety, 2018
Wei Liu, P. Antonelli, P. Dahm, T. Gerhard, Joseph A. C. Delaney, R. Segal, S. Crystal, A. Winterstein   +7 more
semanticscholar   +1 more source

Targeting key proximal drivers of type 2 inflammation in disease

Nature Reviews Drug Discovery, 2015
Gianluca Pirozzi
exaly  

Inventing the dynamo machine: the evolution of the F-type and V-type ATPases

Nature Reviews Microbiology, 2007
Armen Mulkidjanian, Michael Y Galperin
exaly